Trial Profile
Effect of canagliflozin in type 2 diabetic patients with microalbuminuria in Japanese population
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2022
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Antihyperglycaemics
- Indications Proteinuria; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CANPIONE study
- 01 Aug 2022 Results (n=98) published in the Diabetes, Obesity and Metabolism
- 14 May 2020 Status changed from recruiting to discontinued.
- 12 Nov 2018 Status changed from not yet recruiting to recruiting.